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Objective: The role of B cells in the pathogenesis of Takayasu arteritis (TA) is contro-
versial. We aimed to study the presence of tertiary lymphoid organs (TLOs) in the aortic 
wall of TA patients.
Methods: Hematoxylin and eosin-stained sections from aorta specimens from patients 
with TA were screened for TLOs. The presence of B cell aggregates (CD20), follicular 
dendritic cells (FDCs, CD21), and high endothelial venules (HEVs, PNAd) was investi-
gated by immunohistochemistry. Immune cells from the adventitial layer of one patient 
were characterized by flow cytometry. Demographic, medical history, laboratory, imag-
ing, treatment, and follow-up data were extracted from medical records.
results: Aorta specimens from Bentall procedures were available from seven patients (5 
females, aged 22–57 years) with TA. Surgical treatment was performed at TA diagnosis 
(n = 4) or at a median of 108 months (84–156) after TA diagnosis. Disease was active 
at surgery in four patients according to NIH score. B cell aggregates-TLOs containing 
HEVs were observed in the adventitia of all but one patient. Of note, ectopic follicles 
containing CD21+ FDCs were found in all patients (4/4) with increased aortic 18F-fluoro-
deoxyglucose (FDG) uptake before surgery but were absent in all but one patients (2/3) 
with no FDG uptake. In addition, flow cytometry analysis confirmed the accumulation of 
memory/germinal center-like B cells in the adventitial layer and showed the presence of 
antigen-experienced T follicular helper cells.
conclusion: Ectopic lymphoid neogenesis displaying functional features can be found 
in the aortic wall of a subset of patients with active TA. The function of these local B cell 
clusters on the pathogenesis of TA remains to be elucidated.
Keywords: tertiary lymphoid organs, Takayasu arteritis, B cells, immunopathogenesis
TaBle 1 | Patients’ baseline characteristics.
Patients P01 P02 P03 P04 P05 P06 P07
Sex F F M F M F F
Age 57 26 22 41 42 34 32
Smoker Yes Yes No No Yes No Yes
Dyslipidemia Yes No No No No Yes No
Hypertension Yes No Yes No Yes Yes Yes
Diabetes No No No Yes No No No
BMI (kg/m2) 24 24.8 22.8 23 26.6 33.3 21.1
Diagnosis delay (months) 11 3 29 82 96 32 13
Systemic features Yes No No Yes Yes Yes Yes
Vascular features No Yes Yes Yes No Yes Yes
C-reactive protein (mg/L) 68 1 4 48 106 11 75
Aortic lesions (type) IIa (C+P−) V (C+P+) V (C−P−) V (C−P−) IIb (C−P+) V (C−P−) IIb (C−P−)
Disease activity score 3 2 2 4 3 4 4
BMI, body mass index; the type of aortic lesions was defined according to international criteria (14); the disease activity score was assessed according to NIH criteria (12).
Systemic features referred to fatigue (n = 4), headache (n = 2), weight loss (n = 1), dizziness (n = 1), arthritis (n = 1), visual disturbance (n = 1), or erythema nodosum (n = 1).
Vascular features referred to carotid or subclavian bruit (n = 4), claudication with a diminished or absent pulse (n = 4) and carotidodynia (n = 2).
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inTrODUcTiOn
Takayasu arteritis (TA) is a rare primary vasculitis affecting large 
arteries, especially the aorta, the aortic arch, and its main branches. 
The etiology of TA is unknown even if it has been proposed that 
infectious agents play a significant role in the pathogenesis of 
this disease (1). In addition, while T cells exhibiting a Th1 profile 
have been implicated in the pathogenesis of TA (1, 2), the role of 
humoral immunity remains to be elucidated.
Tertiary lymphoid organs (TLOs) are ectopic lymphoid 
structures that form at sites of chronic inflammation through a 
process referred as lymphoid neogenesis. TLOs have morphologic 
features of secondary lymphoid organs including post-capillary 
high endothelial venules (HEVs) allowing homing of naive cells 
in the T cell area, an interface between T and B cell zones and 
germinal center (GC) areas. TLOs have been described in auto-
immunity, microbial infection, cancer, chronic allograft rejection, 
atherosclerosis models, and abdominal aortic aneurysms (3–5). 
Studies have pinpointed the presence of lymphoid aggregates in 
the aortic wall of TA patients without distinguishing them from 
granulomas and have suggested their implication in the physi-
opathology of TA (6, 7). In addition, pathogenic B cells producing 
autoantibodies against endothelial cells are found in the blood 
stream of active TA patients, which suggests that these B cells 
could be activated within the adventitial layer before recirculating 
(8). Finally, some TA patients with active disease have a dramatic 
increase of circulating plasmablasts that are efficiently targeted by 
depleting anti-CD20 antibodies (9).
We aimed at characterizing the peri-aortic lymphoid aggre-
gates developing in TA patients and at analyzing whether their 
presence could be associated with the activity of the disease.
MaTerials anD MeThODs
Patients
We conducted a retrospective multicenter study of patients with 
TA in whom aortic surgery was performed and aortic tissue 
specimen was available for analysis. All patients fulfilled the 
American College of Rheumatology and the Sharma-modified 
Ishikawa criteria for TA (10, 11). Demographic, medical history, 
laboratory, imaging findings, including 18F-fluoro-deoxyglucose 
positron emission tomography (FDG-PET), computed tomog-
raphy angiography (CTA), and/or magnetic resonance imaging 
(MRI), treatment, and follow-up data were extracted from medi-
cal records. The patients’ clinical, laboratory, and imaging data, 
as well as treatments were analyzed at disease onset and at time 
of surgery. Routine laboratory tests, including C-reactive protein 
levels, were collected, and disease activity was defined according 
to the NIH criteria (12). Disease was considered active if NIH 
score was 2 or more, and inactive otherwise.
immunohistochemistry on aortic samples
Aorta tissues were fixed in 4% PFA, embedded in paraffin, and 
sectioned at 6 μm. The sections were deparaffinized in toluene, 
hydrated in ethanol, and incubated in retrieval reagent (R&D 
Systems) for 20 min. After blocking in 5% BSA, the slides were 
incubated with purified primary antibody (mouse anti-human 
CD20, clone L-26; rabbit anti-human CD3, polyclonal, Dako; 
rat anti-human PNAd, MECA-79, BD Biosciences; rabbit 
anti-human CD14, clone EPR3653; rabbit anti-human CD21, 
clone EP3093, Abcam; mouse anti-human CD15, clone HI98, 
Biolegend) overnight at 4°C. After several washes with PBS, sec-
tions were incubated with the appropriate secondary antibody 
(polyclonal goat anti-rabbit DyLight649; goat anti-mouse rhoda-
mine; goat anti-rat rhodamine; donkey anti-mouse rhodamine, 
Jackson Immunoresearch) at RT for 30  min and then cover 
mounted using Prolong Gold Antifade Reagent® (Invitrogen) for 
microscopy. The resulting fluorescence was detected with a Zeiss 
Axiovert 200 M microscope equipped with an AxioCam MRm 
version 3 camera, an ApoTome® system, and AxioVision® image 
capture software.
Flow cytometry analysis
Adventitial layer samples from the aorta were weighed, cut into 
small pieces (<1 mm), and digested using a previously described 
protocol (13). After a wash step, the cells were incubated with 
TaBle 2 | Patients’ characteristics at surgery.
Patients P01 P02 P03 P04 P05 P06 P07
general features
Sex F F M F M F F
Age at diagnosis (years) 57 26 22 41 42 34 32
Age at surgery (years) 57 33 22 41 51 34 45
C-reactive protein (mg/L) 35 33 4 9 4 11 1
Disease activity score 2 2 2 0 1 3 0
Corticosteroid treatment No Yes No No Yes No Yes
Immunosuppressive drugs No No No No No No Yes
Antiplatelet treatment No Yes No No Yes No Yes
Statin No Yes Yes Yes No Yes No
aortic disease
Wall thickness (mm, CT scan or MRI) 10 NA 7 5 16 5 3.5
Wall contrast enhancement (CT scan or MRI) NA NA No No Yes NA Yes
PET (SUV max) 4.8 0 1.3 0 5.0 0 7.0
Apparent in situ aortic inflammation Yes Yes Yes No No Yes Yes
aorta histological findings
Mononuclear cells infiltrate M, A M, A I, M, A A M, A A I, M, A
Multinuclear giant cells M No M No No No M
Sclerosis A A I, M, A M, A I, A I, A A
Neovascularization No M M M, A M, A No No
Plasma cell No M, A No No M A No
Wall thickness A A I No I, A I, A A
Coexistent atheroma No No No No No Yes Yes
Vasa vasorum thickening Yes No No No No No Yes
Interruption of elastic lamina Yes Yes Yes Yes Yes Yes Yes
Granuloma M No No No No No M
Tertiary lymphoid organ A A A No A A A
CD21+ FDCs ++ ++ + − + − ++
PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; FDCs, follicular dendritic cells; SUV max, maximal standard uptake values; 
I, intima; M, media; A, adventitia; NA, not available.
The disease activity score was assessed according to NIH criteria (12).
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LIVE/DEAD® Fixable Yellow Dead Cell Stain Kit (Molecular 
Probes) and stained with the following antibodies: mouse anti-
human CD19 brilliant violet 785, clone HIB19 (Biolegend); 
mouse anti-human CD45 eFluor 605, clone HI30 (eBioscience); 
mouse anti-human CD3 eFluor 450, clone OKT3 (eBiosci-
ence); mouse  anti-human  CD4 PE-CF594, clone UCHL1 (BD 
Biosciences); mouse anti-human HLA-DR APC-H7, clone L234; 
mouse anti-human CD27 brilliant violet 421, clone M-T271; 
mouse anti-human IgD APC, clone IA6-2; mouse anti-human 
CD95 FITC, clone DX2 (BD Biosciences); rate anti-human 
CXCR5 FITC, clone rf8b2 (BD Biosciences); mouse anti-PD-1 
PerCP-Cy 5.5, clone EH1 2.1 (BD Biosciences); mouse anti-
human CD45RA V450, clone HI100 (BD Biosciences); mouse 
anti-human Bcl6 PE, clone IG191/A8 (Biolegend). Flow cytom-
etry analysis was performed using an LSR II flow cytometer (BD 
Biosciences). Data were analyzed with DIVA (BD Biosciences) 
and FlowJo (TreeStar) software.
ethical statement
Our study is a retrospective human non interventional study where 
subjects were not assigned to treatment; they were assigned to a 
diagnosis strategy within the current practice; the study involved 
products with a marketing authorization that are prescribed in 
the usual manner and used in accordance with authorizations by 
French agencies; epidemiological methods were used to analyze 
the data; and information used in the study were collected for 
clinical care. According to the Public Health French Law (art 
L 1121-1-1, art L 1121-1-2), written consents and IRB approval 
are not required for human non interventional studies. Patients 
were however informed that data collected in medical records 
might be used for research study in accordance to privacy rule. 
The study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki.
resUlTs
Patients’ characteristics at Disease Onset 
and Medical Treatment
Aorta specimens were available from 16 patients with TA who 
underwent surgery between 2009 and 2014. Nine patients were 
excluded because diagnosis criteria for TA were not met (n = 7) 
or data were missing (n =  2). Seven patients (five females and 
two males) who fulfilled American College of Rheumatology 
and Ishikawa criteria for TA were studied. The median age at TA 
diagnosis was 34  years (22–57). Diabetes mellitus and dyslipi-
demia were present in cases 1 (14.3%) and 2 (28.6%), respectively. 
FigUre 1 | granulomas versus tertiary lymphoid organs (TlOs) in Ta 
patients. Hematoxylin and eosin staining showing the presence of 
granuloma [first column (a)] in the aortic wall identified as 
CD14++CD20−CD21− cell aggregates by using a combination of CD21 (blue) 
CD20 (brown) [first column (B)] and CD14 (blue) CD20 (brown) [first column 
(B)] staining. Other cell aggregates also visible on hematoxylin and 
eosin-stained sections [second column (a)] are instead TLOs structures 
displaying few CD14+ cells (blue), many CD20+ B cells (brown), and CD21+ 
FDCs (blue) (B). Representative picture (c) showing the distribution of 
granulomas (CD14++) in contact with the medial layer and TLOs (CD20++) 
located deeper within the adventitial layer. Orcein staining (D) suggests that 
granulomas are physically implicated in medial destruction, whereas TLOs 
might develop in response to sustained inflammation in the adventitia.
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Tobacco use was reported in four (57.1%) patients. No patients 
had past history of tuberculosis. The median body mass index was 
23.5 kg/m2 (21.1–33.3). The country of origin was France (n = 4), 
Morocco (n = 1), Mali (n = 1), and West Congo (n = 1).
At disease onset, patients suffered from fatigue (n = 4), head-
ache (n = 2), carotidodynia (n = 2), weight loss (n = 1), dizziness 
(n = 1), arthritis (n = 1), visual disturbance (n = 1), and erythema 
nodosum (n = 1). No patients had fever. One patient was asymp-
tomatic but had asymmetric blood pressure. Hypertension was 
present at onset (n = 4) or occurred (n = 1) during the course of 
the disease. The median delay between the onset of first symptoms 
and the diagnosis of disease was 29 months (3–96).
Serum C-reactive protein levels were raised in five (71.4%) 
patients [median 68  mg/L (11–106)]. At TA diagnosis, disease 
was considered active (NIH score ≥2) in all patients. CT angi-
ography of the aorta was performed at TA diagnosis and showed 
multiple arterial lesions in all patients. Aorta was involved in all 
cases (Table 1).
All patients received glucocorticoids as first-line treatment. 
Methotrexate (n = 3), infliximab (n = 2), azathioprine (n = 1), 
and tocilizumab (n = 1) were prescribed during follow-up in four 
patients.
Patients’ characteristics at surgery
Surgery was performed at the time of first diagnosis in four 
patients or during follow-up (84–156 months) in three patients. 
Disease was active at time of surgery in four patients with a 
NIH score ranging from 2 to 3, including recent ischemic vas-
cular claudication (n = 2), new upper limb bruit (n = 1), and/
or C-reactive protein >10 mg/L (n = 3). Aortic CT angiography 
displayed an increased circumferential aorta wall thickness (3.5–
16 mm, median 7 mm). PET showed an increased FDG uptake 
in the vascular wall of the thoracic aorta wall in four cases. Three 
patients, including one with active disease, were still receiving 
glucocorticoids at time of surgery with a daily dose <10 mg. One 
patient was under tocilizumab. Antiplatelet treatment and statin 
were given in cases 3 and 4, respectively (Table 2).
Fourteen vascular procedures were done in seven patients 
(1–3 per patient, mean 1.7). Indications for surgery were aortic 
regurgitation due to thoracic aneurysm (n = 7) and abdominal 
aorta stenosis with lower limb chronic ischemia (n = 1).
Specimens from the thoracic aorta were obtained from Bentall 
procedures in all cases. At surgery, peri-aortic inflammation was 
obvious in five patients. Microscopically, prominent fibrosis was 
observed in intimal (n = 3), medial (n = 2), and adventitial (n = 7) 
layers, associated with increased intimal (n = 3) and adventitial 
(n = 5) thickness. Medial or adventitial inflammation was seen in 
all cases and involved mononuclear cells (n = 7), giant cells (n = 3), 
and plasma wall cells (n = 3). The deep portion of the media (n = 4) 
and adventitia (n = 2) contained neovessels. Atherosclerotic lesions 
were detected in two aortic specimens (Table 2).
Tertiary lymphoid Organs in the aortic 
Wall
Combination of CD14, CD20, and CD21 staining allowed 
identification of active TLOs (>90% CD14lowCD20+CD21+) and 
FigUre 2 | Distinct features of granulomas and TlOs. Granulomas were made of clusters of CD14+ cells and of CD15+ cells (a,B) where very few B cells  
(inset 1) could be detected. Granulomas were also characterized by an intense angiogenesis [CD31+ vessels (c) and inset 2]. These adventitial neovessels were 
PNAd− (c). Few podoplanin + lymphatic vessels were also associated with blood vessels [(c) and inset 2]. At variance, CD31+ blood vessels with endothelial cells 
displaying a high endothelial venule phenotype and expressing PNAd [(e) and inset 4] were systematically observed within the B cell clusters [(D) and inset 3] that 
are composed of TLOs. A rich network of CD31+ Podoplanin+ lymphatics was detected around TLOs [(e) and inset 5].
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distribution patterns of granulomas and TLOs were distinct: 
granulomas were in contact with the medial layer, whereas 
TLOs were located deeper in the adventitial layer (Figure  1). 
Of note, TLOs (CD20+ clusters) contained a dense network of 
granulomas (>90% CD14++CD20−CD21−) in the vessel wall. 
TLOs were observed in the aortic wall in all but one patient. 
Granulomas were made of macrophages/neutrophils (CD14+/
CD15+) and identified in only two patients. Interestingly, 
FigUre 3 | FDg-PeT-cT imaging in Ta patient. Coronal (a), sagittal (B), 
and axial (c) slices of the thoracic aorta with FDG-PET imaging in P05. Note 
the presence of a linear, high FDG uptake in the ascending thoracic aorta on 
PET corresponding to the anterior region of the aortic wall from an aortic 
aneurysm on corresponding CT images. The left and the right imaging are, 
respectively, 18FDG PET and fused PET/CT images showing high tracer 
uptake on the ascending aorta (Red arrows). Hematoxylin and eosin staining 
(D) of CD21+ (blue) CD20+ (brown) TLOs in the adventitial layer of the aortic 
wall of the same P05 patient.
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HEVs (PNAd+) able to recruit naive cells from the periphery. No 
HEVs were detected within or around CD14+/CD15+ granulo-
mas (Figure 2). Of note, the presence of TLOs in the aortic wall 
was associated with FDG uptake measured by PET-CT scanner 
(Figure 3). Indeed, ectopic follicles containing CD21+ follicular 
dendritic cells (FDCs) were found in all patients with increased 
aortic FDG uptake before surgery, but were absent in all but one 
(2/3) patients with no FDG uptake (Table 2).
Memory B cells and antigen-experienced 
T Follicular helper cells in the aortic Wall
Patient 1 (P01) had a Bentall procedure for aortic regurgitation 
due to thoracic aortic aneurysm (Tables  1 and 2, for clinical 
details). CTA and FDG-PET revealed active aortic lesions in the 
ascending aorta and the aortic arch at surgery time.
Flow cytometry analysis of digested fresh tissue samples con-
firmed the accumulation of live (LIVEDEAD®-negative) B cells 
(CD45+CD19+HLA-DR+) in the inflammatory adventitial layer 
of the middle of the aneurysm, as compared to the neck (the por-
tion of the aneurysm that is contiguous with the normal aorta). 
Local activation of B cells was suspected because most B cells 
had a memory-like phenotype (CD27+IgD−) and some harbored 
a GC-like phenotype (CD95+CD24−IgD−CD27high) (Figure  4). 
In addition, flow cytometry analysis of adventitial tissue samples 
revealed an increase in CD4+ T cells in the core of the aneurysm, 
most of which had a memory phenotype (CD45RA−). Interestingly, 
T follicular helper (Tfh) cells (PD1+CXCR5+Bcl6high) were present 
in the aortic wall as well and were antigen-experienced (CD27−) 
(Figure 4).
DiscUssiOn
Takayasu arteritis is a rare form of chronic large vessel vasculitis 
of unknown origin involving the aorta and its major branches. 
Over the last decades, T cell-mediated immunity and inflamma-
tion have been implicated in the pathogenesis of this disease. Our 
data show that ectopic lymphoid neogenesis takes place in the 
aortic wall of patients with active TA and highlight the role of 
B cells in TA.
Using immunohistochemical examination, mature TLOs were 
detected in the adventitia of all but one TA aortic specimen. The 
accumulation of B cells within the adventitia, as well as their 
organization in TLOs suggests that B cells infiltrate the aortic wall 
in TA. The structural similarities between TLOs and B cells follicles 
found in secondary lymphoid organs suggest a local recruitment 
of naive cells via HEV (PNAd+), their activation, as well as the 
establishment of an immunological humoral memory supported 
by Tfh cells. We detected by immunostaining both TLOs and 
granulomas, each displaying distinct cellular composition and 
occupying different vascular niches. This suggests different func-
tions and involvement in the activity of the disease with TLOs 
enhancing the destructive properties of granulomas and vice versa.
Analysis of immune adventitial cells revealed a high percent-
age of memory and antigen-experienced CD4+ T cells and also 
the presence of cells expressing canonical Tfh cell markers, such as 
CXCR5, Bcl6, and PD-1. These cells orchestrate B-cell activation, 
proliferation, and function (15). TLOs development and main-
tenance in TA may thus depend on the Tfh cell compartment as 
recently reported in atherosclerosis-prone mice (5). In addition, 
patients with TA are known to have enhanced interleukine-6 (IL-
6) serum levels that parallel disease activity (16) and inhibition of 
IL-6 by the monoclonal anti-IL-6 receptor antibody tocilizumab 
is clearly efficient in TA (17). Interestingly, IL-6 is essential for B 
and Tfh cell differentiation (18) suggesting that immunotherapy 
against IL-6 could have dampened TLO development in the 
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FigUre 4 | accumulation of memory B cells, germinal center B cells, and cD4+ T follicular helper cells in the adventitia of Ta diseased aortas.  
(a) Accumulation of immune cells (Viability−CD45+) and B cells (HLA-DR+CD19+) analyzed by flow cytometry in the adventitial layer of the core of the aortic lesions of 
a TA patient (P01) as compared to the neck of the same sample. (B) Characterization of B cells in the adventitia of the aortic lesion by flow cytometry shows that 
most B cells have a memory phenotype (CD27+IgD−) with some harboring a germinal center phenotype (CD95+CD24−IgD−CD27high). (c) Flow cytometry analysis of 
adventitial tissue samples reveals an increase in CD4+ T cells in the aortic lesion (top panel), as well as the presence of CD4+ T cells harboring a Tfh cell phenotype 
(PD1+CXCR5+), as compared to aortic tissues sampled in the aneurysmal neck. (D) CXCR5+CD4+ T cells from the adventitia of the core aortic lesion are Bcl6high.  
(e) CD4+ T cells from the adventitia of the neck (gray), non-Tfh cells (CXCR5−Bcl6−; Red), and Tfh cells (CXCR5+Bcl6high; blue) were analyzed for CD27 and CD45RA 
expression. As compared to CD4+ T cells from the neck, which are a mixture of naive and antigen-experienced (CD27−) and memory cells (CD45RA−), the adventitia 
of the core of the aortic lesion contains more antigen-experienced and no naive T cells (CD45RA+). Interestingly, Tfh cells in the adventitia are CD45RAint and display 
an antigen-experienced phenotype (CD27−).
inflamed arteries of TA patients. Thus, our data suggest that the 
TLOs in TA can support antigen-driven clonal expansion and 
diversification and contain key elements for driving an immune 
pathogenic response that could last for decades if long lived 
plasma cells and memory CD4+ T cells are generated.
Tertiary lymphoid organs can develop in inflamed tissues with a 
frequency that varies greatly depending on the anatomical sites and 
diseases. Ectopic lymphoid tissue and lymphoid neogenesis have 
been observed in infection or immune disorders, including syno-
via in rheumatoid arthritis (19), salivary glands of patients with 
Sjogren’s syndrome (20), multiple sclerosis, inflammatory bowel 
diseases, and allografts (4). Although we still do not know what 
antigenic stimuli trigger their formation, TLOs cannot be consid-
ered as simple passive bystander markers of tissue inflammation 
because they are able to promote auto- or allo-antibody production 
and activating cellular effectors resulting in organ damage such as 
chronic inflammatory disorders and allograft rejection (3, 4).
In conclusion, TLOs are detected in the aortic adventitia of 
TA and comprise Tfh cells, clearly implicating B-cells in active 
TA. Deciphering whether TLOs are functional and allow the 
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maturation of B cells and the production of antibodies remain to 
be formally demonstrated. In addition, understanding the respec-
tive involvement of local immunological reactions associated with 
TLO and granuloma formation in the pathogenesis of TA, as well 
as deciphering the cell types involved and the distinctive factors 
triggering the formation of each type of leukocyte aggregates, will 
lead to the development of new therapeutic approaches to treat 
patients with TA.
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